ProNephro
AKI™ (NGAL)
The first FDA-cleared test for pediatric acute kidney injury risk assessment
Together we play a vital role in changing the course of acute kidney injury (AKI)
The Problem
AKI is a silent epidemic among hospitalized patients—affecting more than 1 in 4 childreni and 1 in 5 adults.ii Earlier AKI risk assessment can inform treatment decisions, minimize unnecessary intervention, and improve patient outcomes.
Revolutionizing Pediatric AKI Risk Assessment
BioPorto welcomes ProNephro AKI (NGAL) to its family of NGAL products in the race against kidney damage – the first FDA-cleared test for pediatric acute kidney injury risk assessment. ProNephro AKI (NGAL) for the Cobas® c 501 clinical chemistry analyzer is available to order through Roche Diagnostics.
*ProNephro AKI is FDA-cleared for use in the US; available through Roche Diagnostics.
Join us in changing the kidney care paradigm
Stay up to date with the latest resources for kidney care, and news about BioPorto.